Jesus Abraham Simón Campos

Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron et al. · The Lancet · 2021 · 230 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Hugh Montgomery, Richard Hobbs, Francisco Padilla et al. · The Lancet Respiratory Medicine · 2022 · 223 citations · Full text

Covid-19 Pandemic, Antiviral Therapy, Placebo-controlled Trial +4

Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate

M. C. Genovese, A. Covarrubias, G. Léon et al. · Arthritis & Rheumatism · 2011 · 194 citations · Full text

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 131 citations · Full text

Critical Care Medicine, Clinical Infectious Disease, Anti-c5a Antibody +6

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

Jennifer Hammond, Robert J. Fountaine, Carla Yunis et al. · New England Journal of Medicine · 2024 · 118 citations · Full text